Journal Club - Recent Additions

November - 2020


Showing Journal 1 of 4

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

J Goldman, D Lye, D Hui, etal for the GS-US-540-5773 Investigators New Eng J Med, 2020., 383:1827-37


The RNA polymerase inhibitor remdesivir has shown nanomolar in-vitro activity against SARS-CoV-2 in human airway epithelial cells and clinical and virologic efficacy in a primate model of SARS-CoV-2. It has safety data in humans infected with Ebola virus. 

This randomised,...


Previous Comments

No Comments yet.